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Introduction: Mutations in Ras family genes are rare in malignant
mesothelioma. The role of activation of the Ras signaling pathway in
the pathogenesis of mesothelioma is not clear.
Methods: We studied the activation status of the Ras pathway and
the status of other Ras-associated kinases in a panel of human
mesothelioma cell lines. In addition, we tested the effect of inhibi-
tion of several kinase pathways on mesothelioma cell proliferation.
The potential role of kinase signaling on the regulation of cap-
dependent translation was also studied.
Results: In general, Ras-guanosine triphosphate (GTP) was higher
in mesothelioma cell lines when compared with a nontransformed
mesothelial cell line (LP9). Furthermore, known Ras effectors such
as extracellular-regulated kinase 1/2, p38 mitogen-activated protein
kinase, and c-Jun N-terminal kinase were found to be active in most
of the mesothelioma cell lines tested. Exposure to specific inhibitors
of extracellular-regulated kinase 1/2 (U0126) and c-Jun N-terminal
kinase (SP600125) significantly decreased the proliferation of
H2596 and H2373 cells compared with mock-treated cells.
SP600125-mediated c-Jun N-terminal kinase inhibition, but not
extracellular-regulated kinase 1/2 inhibition, resulted in a decrease
in phosphorylation of 4E-BP1, consequently decreasing cap-depen-
dent activation.
Conclusions: These experiments provide a rationale for targeting
Ras and associated signaling pathways in mesothelioma and also
suggest cap-dependent translation as one mechanism by which Ras
induces proliferation in this disease.
Key Words: Ras, Mesothelioma, Translation, Cap dependent, Eu-
karyotic initiation factor 4E, Eukaryotic initiation factor 4E.
(J Thorac Oncol. 2007;2: 789–795)
Activation of the Ras signaling cascade plays an importantrole in the induction of proliferation of mammalian cells.
Deregulation of Ras signaling has been found to be an
important characteristic of many cancers. Ras mutations are
found in as many as 30% of human cancers,1 leading to
characteristic activation of downstream signaling pathways.
When Ras is in the GTP-bound form, it activates several
downstream kinase pathways such as Raf/mitogen-activated
protein kinase (MAPK), phosphotidylinositol-3=-kinase/Akt,
and stress-activated protein kinase/c-Jun N-terminal kinase
(JNK). Constitutive activation of the Ras pathway does not
necessarily require mutations in Ras because upstream sig-
nals from receptor tyrosine kinases can activate signaling
resulting in the characteristic changes associated with cancer
cells including the evasion of apoptosis, proliferation, and
tissue invasion.1 The phenomenon of Ras pathway activation
in the absence of mutation has been reported in other cancers
such as prostate and breast cancers.2,3 In the absence of Ras
mutations, upstream activation can occur through extracellu-
lar signaling via receptor tyrosine kinases (RTKs). Similarly,
downstream effectors of Ras can be activated in a Ras-GTP–
independent manner as well.
Malignant mesothelioma, a cancer of the serosal lining
of the pleura or peritoneum, is notable in that many of the
commonly mutated genes associated with cancer, such as Ras
and p53, are rarely targeted. Ras has not been found to be
mutated in mesothelioma cell lines or tumor specimens.4–7
However, signaling pathways can be activated in mesotheli-
oma via several mechanisms that lead to a similar pheno-
type.8 Several RTK pathways have been shown to be acti-
vated in mesothelioma including the epidermal growth factor
receptor, insulinlike growth factor receptor, and c-MET9–12,
all of which activate Ras signaling. Furthermore, epigenetic
inhibition of RASSF1A has been shown to exist in mesothe-
liomas as well. We believe that Ras signaling is important in
mesothelioma pathogenesis and that pharmacologic inhibi-
tion of Ras and its associated effector kinases could be
effective in mesothelioma treatment.
We characterized the activity of components of the Ras
pathway in mesothelioma cell lines compared with nontrans-
formed mesothelial cells and demonstrate that Ras and asso-
ciated downstream kinases are activated in mesothelioma.
Furthermore, we show that inhibition of downstream effec-
tors of Ras signaling decreases proliferation of mesothelioma
cell lines in culture. Finally, by demonstrating that after
inhibition of Ras effectors, there is a concomitant decrease in
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cap-dependent translational activation, we show that transla-
tional control is a potential mechanism by which Ras signal-
ing effects mesothelioma cells.
MATERIALS AND METHODS
Cell Lines and Reagents
All cell lines were purchased from the ATCC or pro-
vided by Frederick Kaye (National Institutes of Health).
H2052, H2373, H2461, H2595, H2596, and H2691 mesothe-
lioma cell lines were grown in RPMI 1640 supplemented
with 10% fetal calf serum.13 The nontransformed human
mesothelial cell line LP9 was obtained from the National
Institute on Aging Aging Cell repository at passage 5. These
cells were isolated from the non-neoplastic peritoneum of an
ovarian cancer patient. The karyotype is normal female dip-
loid (46XX). LP9 cells were maintained in a medium con-
taining a 1:1 ratio of M199 and MCDB10 basal medium
(Sigma), supplemented with 15% fetal bovine serum, and 0.4
g/ml hydrocortisone.
Ras Mutation Analysis
Genomic DNA from each mesothelioma cell line was
isolated from cells using a DNA extraction kit (Amersham
Biosciences). DNA was quantified and sequenced using primers
and subjected to PCR amplification. Codons 12 and 13 of K-ras
were sequenced using dideoxy termination as previously de-
scribed.14
Ras Activity Assay
The Ras activation assay kit (Upstate Inc.) was used for
these studies per manufacturer’s recommendation. Cells were
grown in regular growth medium until they reached approx-
imately 70% confluence and then lysed using an Mg2 lysis
buffer (125 mM HEPES, pH 7.5, 750 mM NaCl, 5% NP-40,
50 mM MgCl2, 5 mM ethylenediaminetetraacetic acid, and
10% glycerol). Raf-1 Ras-binding domain agarose was added
to lysates followed by incubation overnight at 4°C. Beads
were washed twice, and bound Ras-GTP (active form) was
detected by immunoblot with a pan anti-Ras antibody (clone
RAS 10).
In Vitro Kinase Assays
Ras downstream effector activity was determined by
nonradioactive in vitro kinase assay kits (Cell Signaling).
Cells were grown in regular growth media to approximately
70% confluence as above and lysed in buffer (20 mM Tris-
HCl; pH 7.5, 150 mM NaCl, 1 mM Na2 ethylenediaminetet-
raacetic acid, 1 mM EGTA, 1% Triton, 2.5 mM sodium
pyrophosphate, 1 mM -glycerophosphate, 1 mM Na3VO4, 1
g/ml leupeptin). Each kinase was immunoprecipitated using
immobilized antibody or substrate and then exposed to aden-
osine triphosphate and a substrate fusion protein and incu-
bated in kinase buffer for 30 minutes at 30°C. Kinase reac-
tions were stopped with 3 sodium dodecyl sulfate sample
buffer and loaded onto sodium dodecyl sulfate–polyacrylam-
ide gel electrophoresis gels. Phosphorylated substrate was
then detected by immunoblot using phospho-specific antibod-
ies. For extracellular-regulated kinase (ERK) 1/2, Akt, JNK,
and p38 activity, Elk-1, GSK-3, c-Jun, and ATF-2 fusion
proteins, respectively, were used as substrate.
Immunoblots
All gels were transferred onto polyvinylidene difluoride
membranes, blocked in 5% milk-TBST for 2 hours at room
temperature or overnight at 4°C. Primary antibodies were
diluted in TBST and incubated overnight at 4°C. For phos-
pho-specific antibodies, blocking and primary antibody dilu-
tions were in 5% bovine serum albumin-TBST. Anti-Ras and
anti-RalA antibodies were obtained from Upstate Cell Sig-
naling. Anti-phospho-c-Jun, anti–phospho-ATF2, anti–phos-
pho-ELK, antibodies were obtained from Cell Signaling. All
antibodies were diluted 1:1000 for immunoblots. Anti–
eukaryotic initiation factor 4E (eIF4E) (BD Biosciences) and
anti–phospho-eIF4E (Cell Signaling) was diluted at 1:500.
Anti-4E-BP1 (Abcam) was diluted at 1:2500, and anti-eIF4G
was diluted at 1:2000 (kindly provided by Nahum Sonenberg).
Anti-poly (ADP-ribose) polymerase (PARP) antibody (Cell
Signaling) was diluted 1:1000.
Cell Proliferation Assay
Seeded into each well of six-well plates were 1  105
of both H2596 and H2373 cells and allowed to grow in
regular growth medium overnight. On the next day, old
medium was removed; each well was washed twice with 1
phosphate-buffered saline and replaced with fresh medium
containing either 20 M U0126 (an extracellular-regulated
kinase pathway blocker), 25 M SP600125 (an inhibitor of
the JNK pathway), or an equal volume of DMSO. At 48
hours, one set of cells was counted and fresh medium con-
taining the appropriate drug or control was added to the other
set for counting at 96 hours. Cell counting at each time point
was done using trypan blue exclusion.
Apoptosis Assay
H2596 and H2373 cells were grown to 50% confluence
on 10-cm plates. The cells were washed with PBS and
replaced with fresh media containing 20 m of U0126, 25
m of SP600125, or an equal volume of DMSO. One plate of
H2596 cells was also treated with 25 nM gemcitabine as a
positive control. After 24 hours, lysates were prepared and
assayed for protein concentration. 50 g of lysate were run
on sodium dodecyl sulfate–polyacrylamide gel electrophore-
sis and subjected to Western blot for PARP.
Cap-Binding Assay
The cap-binding assay was carried out as previously
described.15 Cells grown to 70% confluence were lysed using
freeze-thaw lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM
NaCl, 50 mM NaF, 1 mM EDTA, 10 mM tetrasodium
pyrophosphate, 1 mM phenylmethylsulfonyl fluoride, 5 M
leupeptin, 2 g/ml aprotinin, 1 g/ml pepstatin A, 100 M
Na3VO4, 20 mM -glycerophosphate). Lysate (300 g) was
added to 50 l of a 50% slurry of 7mGTP-Sepharose beads to
isolate eIF4E and its binding partners 4E-BP1 and eIF4G.
Lysates were rotated at 4°C for 2 hours followed by three
washes in freeze-thaw lysis buffer. Proteins bound to the
beads were then eluted by adding 50 L of 3 loading buffer
and boiling at 95°C for 5 minutes. The eluate was then loaded
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onto 8% to 15% gradient sodium dodecyl sulfate–polyacryl-
amide gel electrophoresis, transferred to polyvinylidene di-
fluoride membrane, and then immunoblotted for eIF4E, 4E-
BP1, and eIF4G.
RESULTS
Two cell lines (H2373 and H2052) were previously
characterized and do not harbor K-ras mutations.16 The other
cell lines used in these studies were analyzed for the presence
of K-ras mutations in codons 12 and 13, and none of the cell
lines harbored mutations in K-ras (data not shown).
Even in the absence of activating ras mutations, we
hypothesized that its downstream signaling pathways may be
activated in mesothelioma cell lines. Both mesothelioma cell
lines and nonmalignant mesothelial cells (LP9) were grown
in their respective growth media and analyzed for the steady-
state activity of Ras as well as its downstream effectors. As
shown in Figure 1A, mesothelioma cell lines demonstrated
higher levels of Ras-GTP than LP9 cells, although there is
variability in this activation between cell lines. H2596 cells
had the highest level of Ras-GTP, whereas H2691 had the
least. Total Ras protein levels were not markedly different
between mesothelioma and LP9 cells. Using in vitro kinase
assays, we next determined the steady-state activity of the
Ras downstream effectors ERK1/2 (Figure 1B), Akt (Figure
1C), JNK (Figure 1D), as well as p38 MAPK (Figure 1E).
ERK1/2 and p38 MAPK were more active in mesothelioma
cell lines than LP9 cells. JNK activity was higher in H2373,
H2461, and H2596 cells, but not in H2052 cells. The corre-
lation of Ras-GTP with JNK and p38 activation was not
absolute through all the cell lines tested, although in cell lines
such as H2596 the presence of Ras activation does correlate
with activation of JNK and p38. In these studies, Akt activity
was not significantly different between mesothelioma and
LP9 cells.
To see whether inhibition of either the JNK or ERK
downstream elements had an effect on the growth of me-
sothelioma cell lines, we performed a cell proliferation assay.
In these experiments, specific inhibitors to different effector
pathways were employed: U0126, an ERK-pathway blocker,
and SP600125, an inhibitor of the JNK pathway. U0126
treatment at a concentration of 20 M significantly decreased
the proliferation of mesothelioma cells compared with vehi-
cle-treated cells after 96 hours of treatment. Only transformed
cells were tested in these experiments. SP600125, at a con-
centration of 25 M, significantly decreased proliferation
after only 48 hours. This difference remained significant at 96
hours (Figure 2).We next sought to determine the role of the Ras
pathway signaling in mediating these antiproliferative effects.
Both U0126 and SP600125 led to decreased phosphorylation of
their respective targets (Figure 3). We also assessed the ability of
these agents to induce apoptosis in our panel of mesothelioma
cell lines (Figure 3C). Compared with gemcitabine-treated cells
as a positive control, U0126 and SP600125 do not appear to
cause cleavage of PARP protein, a marker of apoptosis activa-
tion. We concluded that the effect of both of these drugs did not
involve classic induction of apoptosis.
FIGURE 1. Ras signaling activity in mesothelioma cells. (A)
Ras-GTP (active form) pull-down assay. (B) extracellular-regu-
lated kinase (ERK) 1/2 in vitro kinase activity assay detecting
phosphorylation of Elk-1 fusion protein. (C) Akt in vitro ki-
nase activity assay detecting phosphorylation of glucose syn-
thase kinase-3 (GSK-3) fusion protein. (D) c-Jun N-terminal
kinase (JNK) in vitro kinase activity assay detecting phos-
phorylation of c-Jun. (E) p38 mitogen-activated protein ki-
nase (MAPK) in vitro kinase activity assay detecting phos-
phorylation of ATF-2 fusion protein.
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One potential downstream target of Ras signaling that
has a significant impact on cell growth and proliferation is the
regulation of cap-dependent translation.17,18 We and other
investigators have shown that eIF4E, the rate-limiting factor
for initiation of cap-dependent translation, is overexpressed
in breast, prostate, and lung cancers.15,19,20 Furthermore, cap-
dependent translation is regulated by phosphorylation cas-
cades such that phosphorylation of eIF4E and its negative
regulator, 4E-BP1, selectively promotes translation of key
proteins involved in cell growth. Cap-dependent translation is
not well studied in mesothelioma. We sought to characterize
the steady-state translation activity as well as measure the
impact of Ras/MAPK signaling on translation. Figure 4A
shows results of immunoblots of key molecules involved in
the regulation of cap-dependent translation initiation. Total
protein levels of eIF4E were variable among the cell lines.
Compared with LP9 cells, only H2461 and H2596 had obvi-
ously greater total eIF4E levels. Enhanced phosphorylation of
eIF4E in cell lines H2461, H2596, and H2373 cells when
compared with LP9 cells. In addition, in mesothelioma cells
there was also an increased capacity to bind a synthetic 7m
GTP cap as compared to the non-transformed cells. In this in
vitro assay each of the mesothelioma cell lines demonstrated
enhanced cap binding (Figure 4B). Differences in 4E-BP1
phosphorylation did not appear to be significantly different
between LP9 and mesothelioma cells, although the total
levels of 4E-BP1 are quite low in four of the six cell lines. In
asynchronously growing mesothelioma cells, a combination
of phosphorylation of eIF4E and lower 4E-BP1 levels con-
tributes to cap-dependent translation activation.
Having established that cap-dependent translation ap-
pears to be activated in mesothelioma cell lines, we hypoth-
esized that Ras signaling might influence translational activ-
ity. Indeed, MAPK signaling has been shown to lead to eIF4E
phosphorylation in several cell types, however, this has not
been tested in mesothelioma cells.21 Furthermore, the influ-
ence of the stress-activated protein kinases, such as JNK, on
translation is not known. To determine whether these Ras
effector proteins are potentially involved in activation of
cap-dependent translation in mesothelioma cell lines, we
measured the phosphorylation status of eIF4E and 4E-BP1
before and after treatment with the ERK1/2 inhibitor U0126
and the JNK inhibitor SP600125. Figure 5 shows the effects
of inhibition of JNK and ERK1/2 on cap-dependent transla-
tion. Inhibition of ERK1/2 and JNK had little effect on
phosphorylation of eIF4E (Figure 5A). Treatment of H2596
and H2373 cells with U0126 also did not significantly alter
phosphorylation of 4E-BP1 and consequently had no effect
on activation of cap-dependent translation as assessed by the
cap-binding assay (Figure 5B). However, JNK inhibition with
SP600125 markedly decreased the levels of hyperphospho-
rylated 4E-BP1 for both cell lines tested. Consequently, in the
cap-binding assay, an increased amount of 4E-BP1 bound
to eIF4E corresponding to a decrease in activation of cap-
dependent translation. As further evidence that cap-depen-
dent translation is affected by JNK inhibition, we assayed for
vascular endothelial growth factor (VEGF) by immunoblot
after treatment with U0126 and SP600125. VEGF protein
levels are thought to be regulated in part by cap-dependent
translation,20,22 and therefore a decrease in VEGF level
should correspond to a decrease in activation of cap-dependent
translation. VEGF protein levels were markedly lower in the
SP600125-treated cells (Figure 5B). U0126 also decreased
VEGF levels, but to a lesser extent than SP600125. These results
demonstrate that a likely downstream effect of JNK activation in
mesothelioma cells is activation of cap-dependent translation
consequently promoting growth and proliferation.
FIGURE 2. Inhibition of cell prolif-
eration by blockade of Ras down-
stream effectors. (A, B) Cell prolifera-
tion after 48 and 96 hours of
treatment with U0126 in H2596,
H2373, and H2461 cell lines. (C, D)
Cell proliferation after 48 and 72
hours of treatment with SP600125.
All proliferation assays were done in
triplicate.
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DISCUSSION
We have shown that both Ras and associated pathways
are active in mesothelioma cell lines and are potentially
relevant targets for mesothelioma therapy. Increased Ras
pathway activity not only differentiates mesothelioma cells
from nontransformed mesothelial cells, but also that the
interruption of signaling through two downstream Ras effec-
tor kinases decreases cell proliferation of mesothelioma cells,
suggesting these pathways are important for the malignant
phenotype. Furthermore, this study demonstrates that activa-
tion of cap-dependent translation may be an important down-
stream consequence of the Ras signaling pathway. Cap-
dependent translation appears activated in mesothelioma cells
as demonstrated by increased binding of eIF4E to the cap
initiation complex.
Activation of RTKs including endothelial growth fac-
tor, insulinlike growth factor, VEGF, and hepatocyte growth
factor have been proposed for mesothelioma in previous
studies.23,24 Each of these RTKs signal through Ras, suggest-
ing that activation of Ras pathway is important to the pathol-
ogy of mesothelioma. As an example, addition of exogenous
EGF to cells in culture induces activated Ras in mesothelioma
cells.8 Furthermore, epigenetic RASSF1A inactivation has
been shown in mesothelioma, suggesting that the inhibitory
signals to Ras activation may be disabled in mesothelioma
cells.25,26 Although Ras signaling has been shown to have an
impact on all aspects of the malignant phenotype of some
cancer cells, in mesothelioma cells, it appears that Ras sig-
naling has its greatest effect on cell proliferation with little
effect on inhibition of apoptosis. Inhibition of both ERK1/2
and JNK signaling significantly decreased cell proliferation.
However, neither drug appeared to induce apoptosis as as-
sayed by detection of PARP cleavage products.
Interestingly, although both ERK1/2 and JNK inhibi-
tion resulted in decreased cell proliferation, they appear to
work via different mechanisms. Although studies have shown
that ERK1/2, via MNK kinase activity, can directly influence
the phosphorylation of eIF4E, thus favoring cap-dependent
translation, we found that ERK1/2 inhibition had little effect
FIGURE 3. U0126 and SP600125 block the activity of ex-
tracellular-regulated kinase (ERK) 1/2 and c-Jun N-terminal
(JNK), respectively. (A) ERK1/2 activity assay after treatment
with 20 M U0126. (B) JNK activity after treatment with 25
M SP600125. (C) Poly (ADP-ribose) polymerase (PARP)
cleavage assay to assess for induction of apoptosis following
treatment with inhibitors. C, vehicle; U, U0126; S,
SP600125; G, gemcitabine.
FIGURE 4. Evaluation of cap-dependent translation activa-
tion in mesothelioma. (A) Immunoblots in whole cell lysates
for key proteins involved in cap-dependent translation. Iso-
forms of 4E-BP1 indicating progressive phosphorylation (in-
activation) are indicated (, , ). (B) In vitro cap-binding
assay showing the relative amounts of (eukaryotic initiation
factor 4E) eIF4E bound to 7mGTP-Sepharose beads in LP9
and mesothelioma cells. Results are expressed by densitome-
try and immunoblot as described in the text.
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on phosphorylation of eIF4E in mesothelioma cells and did
not appear to affect activation of the cap-dependent transla-
tion complex. Surprisingly, JNK inhibition decreased phos-
phorylation of 4E-BP1. Whether JNK directly leads to alter-
ations in cap-dependent translation or if JNK activation leads
to the activation of other kinases and a consequent increase
in translation remains to be seen and is an area of future
investigation.
It has previously been reported that inhibition of MAPK
resulted in a decrease in mesothelioma cell proliferation.27 Here
we have reproduced those findings and have shown that
Ras/MAPK activity differentiates mesothelioma cells from
nontransformed cells. We believe that the Ras signaling
cascade is a relevant target for the treatment of mesothelioma.
Interestingly, farnesyl transferase inhibitors, a class of agents
that potentially target Ras, have been reported to be toxic to
mesothelioma cells.8,28
It must be noted that these experiments are done on
established cell lines. Further investigations in either animal
models or fresh human mesothelioma specimens are necessary
to confirm the in vivo relevance of these findings to the biology
of this disease. In addition, although JNK and ERK1/2 activation
are known to be dependent on Ras signaling in many tumor
models, these experiments do not rule out the possibility of
Ras-independent mechanisms for activation of these pathways.
Nonetheless, these experiments show that there is a rationale for
targeting Ras and its associated kinase effectors to disrupt the
natural biology of this disease. In addition, the mechanism by
which JNK affects cap-dependent translation and the relevance
this has on the biology of mesothelioma is not clear from these
experiments and will have to be investigated further.
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